MAM
CORT icon

Martingale Asset Management’s Corcept Therapeutics CORT Stock Holding History

Martingale Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-38,625
Closed -$973K – 795
2024
Q1 		$973K Sell
38,625
-30,465
-44% -$720K 0.02% 478
2023
Q4 		$2.24M Sell
69,090
-160
-0.2% -$4.39K 0.05% 263
2023
Q3 		$1.89M Sell
69,250
-9,512
-12% -$275K 0.04% 280
2023
Q2 		$1.75M Buy
78,762
+4,013
+5% +$92.4K 0.03% 305
2023
Q1 		$1.62M Buy
74,749
+1,088
+1% +$23.9K 0.03% 319
2022
Q4 		$1.5M Buy
73,661
+2,603
+4% +$65.2K 0.03% 339
2022
Q3 		$1.82M Buy
71,058
+306
+0.4% +$8.19K 0.04% 270
2022
Q2 		$1.68M Buy
70,752
+57,028
+416% +$1.24M 0.03% 323
2022
Q1 		$310K Sell
13,724
-53,242
-80% -$1.13M ﹤0.01% 721
2021
Q4 		$1.33M Buy
66,966
+2,312
+4% +$46.9K 0.02% 413
2021
Q3 		$1.27M Buy
+64,654
New +$1.35M 0.02% 452

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Martingale Asset Management's CORT Position: Q2 2024 in Review

Martingale Asset Management sold out of Corcept Therapeutics (CORT) in Q2 2024, closing a stake of 38,625 shares — an estimated $973K sold.

Martingale Asset Management first reported a position in CORT in Q3 2021 and held it in 11 quarters. The position peaked at $2.24M in Q4 2023. 286 funds tracked by Wall St. Rank hold CORT as of Q2 2024.

  • Martingale Asset Management reported no remaining Corcept Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Martingale Asset Management sold 38,625 Corcept Therapeutics shares in Q2 2024, an estimated $973K.
  • Martingale Asset Management first reported a position in Corcept Therapeutics in Q3 2021 and held it in 11 quarters.
  • Martingale Asset Management's Corcept Therapeutics position peaked at $2.24M in Q4 2023.
  • 286 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2024.

Based on Martingale Asset Management's 13F filing for Q2 2024, filed 12 Aug 2024.